Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: New product launches scale much faster than anticipated, completely offsetting LOE impacts.
Pipeline Replacement Failure: New assets like Opdualag and Camzyos completely fail to offset the multi-billion-dollar revenue crater from the Revlimid and Eliquis patent cliff.
Bristol-Myers Squibb is trading at distressed multiples (9.1x forward P/E vs 14.1x peer median) as it navigates a significant turnaround phase. The core challenge is a steep patent cliff for blockbusters like Revlimid and Eliquis. We view current pricing as overly pessimistic, anchoring our valuation on structural cash flow resilience.
Bristol-Myers Squibb is trading at distressed multiples (9.1x forward P/E vs 14.1x peer median) as it navigates a significant turnaround phase. The core challenge is a steep patent cliff for blockbusters like Revlimid and Eliquis. We view current pricing as overly pessimistic, anchoring our valuation on structural cash flow resilience.
Economies of Scale
Rapid adoption of next-generation biologics and targeted oncology therapies driving multiple expansion.
Strong Buy. The $84.55 fair value properly prioritizes the company's structural survivability over near-term distressed sentiment.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Bristol-Myers Squibb is facing a massive loss of exclusivity wave. A failure in executing its new product launches would transform its 9.1x distressed multiple into a value trap, threatening the sustainability of its 70% dividend payout.
Economies of Scale
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $11.2B after capex $1.3B, with terminal value at 61.4% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If next quarter shows accelerating pipeline revenue, upside expands. If legacy erosion dominates, expect range-bound trading near $50.
If next quarter shows accelerating pipeline revenue, upside expands. If legacy erosion dominates, expect range-bound trading near $50.
If next quarter shows accelerating pipeline revenue, upside expands. If legacy erosion dominates, expect range-bound trading near $50.
Currently in a heavy reinvestment phase to bridge legacy revenue erosion with novel pipeline assets.
Rapid adoption of next-generation biologics and targeted oncology therapies driving multiple expansion.
Patent cliffs and tightening government pricing regulations compressing industry-wide profitability.
Currently in a heavy reinvestment phase to bridge legacy revenue erosion with novel pipeline assets.
Given the high execution risk of the pipeline turnaround, limit sizing to a moderate weight, scaling up upon confirmed pipeline sales acceleration.
Trim position as shares approach the $84.55 fair value midpoint or if deterioration signals trigger.
Strong Buy. The market's heavy penalization for the near-term patent cliff obscures the company's robust long-term intrinsic cash-flow generation and turnaround potential.
We anchor on the $85.31 FCFF DCF valuation, viewing the distressed forward earnings multiple as an overly pessimistic outlier that ignores structural cash generation.
Strong Buy. The market's heavy penalization for the near-term patent cliff obscures the company's robust long-term intrinsic cash-flow generation and turnaround potential.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Pipeline assets fail to hit peak sales targets. LOE erosion outpaces new product growth, leading to sustained structural decline and potentially dilutive M&A.
New assets like Opdualag and Camzyos completely fail to offset the multi-billion-dollar revenue crater from the Revlimid and Eliquis patent cliff.
Regulatory and pricing pressures under the Inflation Reduction Act permanently compress operating margins well below the projected 29%.
Management pursues aggressively overpriced acquisitions to patch the pipeline gap, significantly destroying ROIC and elevating debt.
The five developments that would weaken our investment case.
Accelerating revenue declines signify that newly commercialized therapeutic assets fail to counterbalance patent cliff losses from mature drugs, impairing top-line stabilization and undermining the foundational growth recovery thesis.
Current:-0.2% for the period ended 2025-12-31
Alert if< -5.0% over any full fiscal year
Compressing operating profitability reflects legislative pricing cuts and loss of exclusivity on high-margin treatments, preventing reinvestment into clinical development while eroding operational leverage across global commercial channels.
Current:28.5% for the period ended 2025-12-31
Alert if< 25.0% over any two consecutive fiscal quarters
Substantial degradation in capital returns indicates that debt-financed acquisitions and business development initiatives are failing to yield hurdle returns, destroying economic value and restricting balance sheet flexibility during revenue troughs.
Current:13.5% as of 2026-05-10
Alert if< 8.0% over any trailing twelve-month period
A decline in cash generation relative to accounting profits signals mounting working capital pressures and reduced underlying cash earnings, constraining internal funding for research laboratories, production facilities, and strategic pipeline reinvestment.
Current:2.007 as of 2026-05-10
Alert if< 1.20 over any full fiscal year
An expanding dividend payout ratio indicates that shrinking post-patent cash flows cannot sustain capital distributions, raising the probability of a dividend cut and destroying the total return thesis for income investors.
Current:70% as of 2026-05-10
Alert if> 80.0% over any trailing twelve-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
New product launches scale much faster than anticipated, completely offsetting LOE impacts. The company returns to mid-single-digit revenue growth.
Near-term contraction is followed by stabilization. The new product portfolio gradually replaces lost legacy revenues, driven by strong free cash flow generation.
If next quarter shows accelerating pipeline revenue, upside expands. If legacy erosion dominates, expect range-bound trading near $50.
Warning level: < -5.0% over any full fiscal year. Accelerating revenue declines signify that newly commercialized therapeutic assets fail to counterbalance patent cliff losses from mature drugs, impairing top-line stabilization and undermining the foundational growth recovery thesis.
Warning level: < 25.0% over any two consecutive fiscal quarters. Compressing operating profitability reflects legislative pricing cuts and loss of exclusivity on high-margin treatments, preventing reinvestment into clinical development while eroding operational leverage across global commercial channels.
Warning level: < 8.0% over any trailing twelve-month period. Substantial degradation in capital returns indicates that debt-financed acquisitions and business development initiatives are failing to yield hurdle returns, destroying economic value and restricting balance sheet flexibility during revenue troughs.
Warning level: < 1.20 over any full fiscal year. A decline in cash generation relative to accounting profits signals mounting working capital pressures and reduced underlying cash earnings, constraining internal funding for research laboratories, production facilities, and strategic pipeline reinvestment.
Warning level: > 80.0% over any trailing twelve-month period. An expanding dividend payout ratio indicates that shrinking post-patent cash flows cannot sustain capital distributions, raising the probability of a dividend cut and destroying the total return thesis for income investors.
| $45.01B |
| $48.30B |
| $48.20B |
| +1.4% |
| Gross profit | $36.02B | $34.31B | $34.33B | $34.26B | -1.7% |
| Operating income | $8.95B | $9.61B | $-6.43B | $11.22B | +7.8% |
| Net income | $6.33B | $8.03B | $-8.95B | $7.05B | +3.7% |
| EPS (diluted) | $2.95 | $3.86 | $-4.41 | $3.46 | +5.5% |
| EBITDA | $19.22B | $19.37B | $3.17B | $15.23B | -7.5% |
| R&D | $9.51B | $9.30B | $11.16B | $9.95B | +1.5% |
| SG&A | $7.81B | $7.77B | $8.41B | $7.27B | -2.4% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 48,195,000,000 |
|---|---|
| Cost of revenue | 13,936,000,000 |
| Gross profit | 34,259,000,000 |
| Operating expenses | 20,535,000,000 |
| Operating income | 13,724,000,000 |
| Non-operating items and tax | -6,670,000,000 |
| Net income | 7,054,000,000 |
| Total assets | 90,038,000,000 |
|---|---|
| Cash | 10,209,000,000 |
| Current assets | 29,390,000,000 |
| Total liabilities | 71,532,000,000 |
| Current liabilities | 23,417,000,000 |
| Shareholders’ equity | 18,473,000,000 |
Point-in-time financial data used in the 2026-05-10 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | 46.2B | 19.2B | 6.3B | 13.1B | 11.9B | 1.1B | 10.3B | 457M | 8B | 4.6B | -5.3B | — | — | — | — | 9.1B | 40.7B | 19.7% | — | 6.3% | — |
| 2023-12-31 | 45B | 19.4B | 8B | 13.9B | 12.7B | 1.2B | 9.8B | 518M | 5.2B | 4.7B | 456M | — | — | — | — | 11.5B | 41.5B | 18.2% | — | 6.0% | — |
| 2024-12-31 | 48.3B | 3.2B | -8.9B | 15.2B | 13.9B | 1.2B | 9.6B | 507M | 0 | 4.9B | 10.1B | — | — | — | — | 10.3B | 51.2B | 12.2% | — | 6.3% | — |
| 2025-12-31 | 48.2B | 15.2B | 7.1B | 14.2B | 12.8B | 1.3B | 4B | 553M | 0 | 5B | -5.2B | — | — | — | — | 10.2B | 47.1B | 28.5% | — | 5.6% | — |
BMY trades at 9.1x forward earnings against a peer median of 14.1x; EV/EBITDA of 7.9x against a peer median of 14.0x; 6 peers.
| Accumulate near current distressed levels (~$56), capturing the strong dividend yield while awaiting turnaround confirmation. |
| Johnson & Johnson |
| 17.4x |
| 5.5x |
| 16.5x |
| 26.4% |
| 27.4% |
| ABBV | AbbVie Inc. | 12.4x | 5.7x | 14.0x | 62.2% | 31.6% |
| MRK | Merck & Co. Inc. | 11.6x | 4.2x | 10.8x | 18.9% | 38.6% |
| AMGN | Amgen Inc. | 14.1x | 4.8x | 13.3x | 101.3% | 33.8% |
